{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:46:46Z","timestamp":1790833606972,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ijantimicag.2020.106248","type":"journal-article","created":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T11:15:37Z","timestamp":1606562137000},"page":"106248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8841-7545","authenticated-orcid":false,"given":"Martin D.","family":"Hellwig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabela","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106248_bib0001","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","article-title":"A novel coronavirus outbreak of global health concern","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0002","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMp2000929","article-title":"A novel coronavirus emerging in China\u2014key questions for impact assessment","volume":"382","author":"Munster","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0003","series-title":"COVID-19 coronavirus pandemic","year":"2020"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0004","article-title":"Polarization and public health: partisan differences in social distancing during the coronavirus pandemic. Working Paper 26946","author":"Allcott","year":"2020","journal-title":"National Bureau of Economic Research"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0005","doi-asserted-by":"crossref","DOI":"10.1088\/1478-3975\/ab9bf5","article-title":"The COVID-19 pandemic: growth patterns, power law scaling, and saturation","volume":"17","author":"Singer","year":"2020","journal-title":"Phys Biol"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0006","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1126\/science.368.6486.14","article-title":"Vaccine designers take first shots at COVID-19","volume":"368","author":"Cohen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0007","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jacbts.2016.03.002","article-title":"Drugs, devices, and the FDA: Part 1: an overview of approval processes for drugs","volume":"1","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0008","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Zhou","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105932","article-title":"Chloroquine and hydroxychloroquine as available weapons to fight COVID-19","volume":"55","author":"Colson","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101615","article-title":"Remdesivir as a possible therapeutic option for the COVID-19","volume":"34","author":"Al-Tawfiq","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0012","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1046\/j.1472-8206.2003.00170.x","article-title":"Ivermectin and filariasis","volume":"17","author":"Richard-Lenoble","year":"2003","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0013","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJM198507183130301","article-title":"Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis","volume":"313","author":"Greene","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0014","doi-asserted-by":"crossref","DOI":"10.2139\/ssrn.3636557","article-title":"Ivermectin for COVID-19 treatment: clinical response at quasi-threshold doses via hypothesized alleviation of CD147-mediated vascular occlusion","author":"Scheim","year":"2020","journal-title":"SSRN"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0015","doi-asserted-by":"crossref","DOI":"10.2139\/ssrn.3631261","article-title":"ICON (Ivermectin in COvid Nineteen) Study: use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19","author":"Rajter","year":"2020","journal-title":"SSRN"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0016","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41429-020-0336-z","article-title":"a systematic review from antiviral effects to COVID-19 complementary regimen","volume":"73","author":"Heidary","year":"2020","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006020","article-title":"Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers","volume":"12","author":"Mu\u00f1oz","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0018","series-title":"PCT Databank","year":"2020"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0019","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/cpt.1889","article-title":"The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19","volume":"108","author":"Schmith","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0020","series-title":"Ivermectin and abamectin","first-page":"113","article-title":"Pharmacokinetics of ivermectin in animals and humans","author":"Fink","year":"1989"},{"key":"10.1016\/j.ijantimicag.2020.106248_bib0021","series-title":"COVID-19 and ivermectin intended for animals","year":"2020"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920304684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920304684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:38:35Z","timestamp":1760377115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920304684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0924857920304684"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106248","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106248"}}